openPR Logo
Press release

Thyroid Eye Disease Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight

06-17-2025 05:04 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Thyroid Eye Disease Market

Thyroid Eye Disease Market

DelveInsight's "Thyroid Eye Disease Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Thyroid Eye Disease, historical and forecasted epidemiology as well as the Thyroid Eye Disease market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Unlock key insights into the Thyroid Eye Disease Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Thyroid Eye Disease Therapeutics Market Outlook- https://www.delveinsight.com/sample-request/thyroid-eye-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Thyroid Eye Disease Market Report
• In April 2025, Tourmaline Bio Inc. announced a study of Phase 2b trial of TOUR006 in Thyroid Eye Disease (TED) to evaluate 20mg and 50mg doses against placebo given by a subcutaneous injection every eight weeks to TED patients who are in the active inflammatory phase of disease.
• In April 2025, Viridian Therapeutics Inc. conducted a study are to determine if VRDN-003 is efficacious, safe and tolerable when administered as subcutaneous/SC injections every 4 weeks or every 8 weeks compared to placebo in participants with chronic TED.
• In April 2025, Amgen organized a study consists of a randomized double-masked, placebo-controlled, parallel-group, multicenter trial with an optional open-label treatment period for proptosis non-responders who complete the Double-masked Treatment Period.
• The total prevalent cases of thyroid eye disease in the United States were around 1,012,000 cases in 2022.
• The US contributed to the largest prevalent population of thyroid eye disease, acquiring ~42% of the 7MM in 2022. Whereas Germany accounted for around 13% and Japan accounted for around 8% of the total population share, respectively, in 2022.
• Among EU4 countries, Germany accounted for the largest number of thyroid eye disease cases, followed by France, whereas Spain accounted for the lowest number of cases in 2022.
• According to DelveInsight estimates, there were around 16,300 cases of acute Thyroid Eye Disease and 41,900 cases of chronic Thyroid Eye Disease in Japan in 2022. These cases are projected to increase during the forecasted period.
• In the 7MM, approximately 20% of the patient share is attributed to males, whereas only 80% of females suffer from thyroid eye disease.
• The diagnosis and treatment rate of thyroid eye disease is expected to increase in the coming years due to the increase in expected approvals of several pipeline candidates for the treatment of thyroid eye disease, thus leading to the increase in awareness among patients and clinicians.
• The leading Thyroid Eye Disease Companies such as Allergan PLC, Eli Lilly & Company, Boehringer Ingelheim, Merck & Co. Inc., Astellas Pharma Inc., Olympus Medical, Butterfly Medical, SRS Medical, Teleflex Interventional Urology, Urotronic, Zenflow, ProArc Medical, Medion Biodesign, and others.
• Promising Thyroid Eye Disease Pipeline Therapies such as RVT-1401, VRDN-003, Batoclimab, Veligrotug (VRDN-001), Teprotumumab, IBI311 and others.

Stay ahead in the competitive landscape of the Thyroid Eye Disease Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Thyroid Eye Disease Treatment Market Size- https://www.delveinsight.com/sample-request/thyroid-eye-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Thyroid Eye Disease Epidemiology Segmentation in the 7MM
• Thyroid Eye Disease Prevalent Cases
• Thyroid Eye Disease Diagnosed Prevalent Cases
• Thyroid Eye Disease Gender-specific Diagnosed Prevalent Cases
• Thyroid Eye Disease Diagnosed Prevalent Cases
• Moderate-to-severe Drug-treated Cases of Acute Thyroid Eye Disease Cases

Download the report to understand which factors are driving Thyroid Eye Disease epidemiology trends @ Thyroid Eye Disease Prevalence- https://www.delveinsight.com/sample-request/thyroid-eye-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Thyroid Eye Disease Marketed drugs
• TEPEZZA (teprotumumab): Horizon Therapeutics
Insulin-like growth factor I receptor (IGF-IR) is implicated as a potential cause of thyroid eye disease, and overexpression of IGF-IR is found in orbital fibroblasts and lymphocytes. Features of thyroid eye disease include periorbital edema, proptosis, strabismus, and eyelid retraction, which can progress to vision-threatening complications, such as exposure keratopathy and compression neuropathy. Current management of this condition is not very effective and includes systemic steroids or radiation of the orbit, both of which are associated with significant adverse effects and complications.

Thyroid Eye Disease Emerging drugs
• Batoclimab: Immunovant Sciences
Immunovant's first investigational product, batoclimab (IMVT-1401), is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). In nonclinical studies and clinical trials, batoclimab has been observed to reduce IgG antibody levels. High levels of pathogenic IgG antibodies drive a variety of autoimmune diseases, and, as a result, this product candidate has the potential to address a variety of IgG-mediated autoimmune diseases as a self-administered SC injection.

To learn more about Thyroid Eye Disease Treatment guidelines, visit @ Thyroid Eye Disease Market Drivers and Barriers- https://www.delveinsight.com/sample-request/thyroid-eye-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Thyroid Eye Disease Treatment Market Landscape
Thyroid eye disease treatment has evolved from nonspecific immunosuppression to targeted biological therapies. Current medical therapies target the active stage to decrease inflammation, minimize the worsening of functional ocular sequel, and in some cases, improve ocular signs, including proptosis and double vision. The mainstay of treatment for years has been steroids and orbital radiation (ORT). Several biologics have been assessed in recent years: rituximab, tocilizumab, and teprotumumab.

Thyroid Eye Disease Market Outlook
Thyroid Eye Disease treatment in the US is entering a new era with changing dynamics. To this date, only one drug has been approved by the US FDA to treat Thyroid Eye Disease: insulin-like growth factor-I receptor antagonist TEPEZZA. It is worth mentioning that the European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines 2021 recommends IV methylprednisolone in combination with oral mycophenolate sodium (or mofetil) as the first-line treatment for moderate-to-severe and acute thyroid eye disease, and in the more severe forms of moderate-to-severe and acute thyroid eye disease, including constant/inconstant diplopia, severe inflammatory signs and exophthalmos >25 mm, IV methyl-prednisolone at the highest cumulative dose (7.5 g per cycle) as monotherapy represents an additional valid first-line treatment.

Explore the dynamics of the Thyroid Eye Disease Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ Thyroid Eye Disease Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/thyroid-eye-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Thyroid Eye Disease Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Thyroid Eye Disease Companies- Allergan PLC, Eli Lilly & Company, Boehringer Ingelheim, Merck & Co. Inc., Astellas Pharma Inc., Olympus Medical, Butterfly Medical, SRS Medical, Teleflex Interventional Urology, Urotronic, Zenflow, ProArc Medical, Medion Biodesign, and others.
• Thyroid Eye Disease Pipeline Therapies- RVT-1401, VRDN-003, Batoclimab, Veligrotug (VRDN-001), Teprotumumab, IBI311 and others.
• Thyroid Eye Disease Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Thyroid Eye Disease Unmet Needs, KOL's views, Analyst's views, Thyroid Eye Disease Market Access and Reimbursement

Table of Content
1 Key Insights
2 Thyroid Eye Disease Market Report Introduction
3 Thyroid Eye Disease Market Overview at a Glance
4 Executive Summary of Thyroid Eye Disease
5 Epidemiology and Market Methodology
6 Disease Background and Overview
7 Thyroid Eye Disease Epidemiology and Patient Population
8 Thyroid Eye Disease Patient Journey
9 Key Endpoints in Thyroid Eye Disease Clinical Trials
10 Thyroid Eye Disease Marketed Therapies
11 Thyroid Eye Disease Emerging Therapies
12 Thyroid Eye Disease: The 7MM Analysis
13 Thyroid Eye Disease Market Access and Reimbursement
14 Thyroid Eye Disease KOL Views
15 Thyroid Eye Disease SWOT Analysis
16 Thyroid Eye Disease Unmet Needs
17 Appendix
18 DelveInsight Capabilities
19 Disclaimer
20 About DelveInsight

List of Top Selling Market Research Reports in 2025

radial artery compression device market- https://www.delveinsight.com/report-store/transradial-access-products-market
vital sign monitors devices market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
cone rod dystrophy market- https://www.delveinsight.com/report-store/cone-rod-dystrophy-market
opioid-related disorders market- https://www.delveinsight.com/report-store/opioid-related-disorders-market
adeno associated viruses aav gene therapy market- https://www.delveinsight.com/report-store/adeno-associated-virus-aav-vectors-in-gene-therapy-pipeline-insight
cystic fibrosis market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
scoliosis market - https://www.delveinsight.com/report-store/scoliosis-market
antibody drug conjugate market - https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
methicillin-resistant staphylococcus aureus infection market- https://www.delveinsight.com/report-store/methicillin-resistant-staphylococcus-aureus-mrsa-market
pediatric brain tumor market- https://www.delveinsight.com/report-store/pediatric-brain-tumors-market
smoking cessation market- https://www.delveinsight.com/report-store/smoking-cessation-and-nicotine-addiction-market
uterine fibroids market- https://www.delveinsight.com/report-store/uterine-leiomyoma-uterine-fibroids-market
atopic dermatitis market- https://www.delveinsight.com/report-store/atopic-dermatitis-market
cardiogenic shock market- https://www.delveinsight.com/report-store/early-cardiogenic-shock-cs-market
chemotherapy induced neutropenia market- https://www.delveinsight.com/report-store/chemotherapy-induced-neutropenia-cin-market
CXCR inhibitors market- https://www.delveinsight.com/report-store/selective-inhibitor-of-the-cxcr4-chemokine-receptor-market-forecast
friedreich's ataxia market- https://www.delveinsight.com/report-store/friedreichs-ataxia-market
herpes labialis market- https://www.delveinsight.com/report-store/herpes-labialis-market
herpes zoster market- https://www.delveinsight.com/report-store/herpes-zoster-market
somatotropin deficiency market- https://www.delveinsight.com/report-store/growth-hormone-deficiency-ghd-market
spinal trauma devices market- https://www.delveinsight.com/report-store/trauma-devices-market
tcr therapy market- https://www.delveinsight.com/report-store/tcr-therapy-market
transcatheter heart valve replacement devices market- https://www.delveinsight.com/report-store/transcatheter-heart-valve-replacement-devices-market
atherosclerosis market- https://www.delveinsight.com/report-store/atherosclerotic-cardiovascular-disease-ascvd-market
carcinoid syndrome market- https://www.delveinsight.com/report-store/carcinoid-tumor-market
cardiac monitoring devices market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
chronic heart failure market- https://www.delveinsight.com/report-store/heart-failure-market
chronic venous ulceration market- https://www.delveinsight.com/report-store/chronic-venous-ulceration-market
diabetic wound market- https://www.delveinsight.com/report-store/diabetic-wounds-market
hypertrophic cardiomyopathy market- https://www.delveinsight.com/report-store/hypertrophic-cardiomyopathy-market
langerhans cell histiocytosis market- https://www.delveinsight.com/report-store/langerhans-cell-histiocytosis-market
liver fibrosis market- https://www.delveinsight.com/report-store/liver-fibrosis-market
membranous nephropathy market- https://www.delveinsight.com/report-store/idiopathic-membranous-nephropathy-imn-market
novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market
pelvic organ prolapse market- https://www.delveinsight.com/report-store/pelvic-organ-prolapse-market
plaque modification devices market- https://www.delveinsight.com/report-store/plaque-modification-devices-market
primary ciliary dyskinesia market- https://www.delveinsight.com/report-store/primary-ciliary-dyskinesia-market
psoriasis vulgaris market- https://www.delveinsight.com/report-store/psoriasis-vulgaris-market
radiodermatitis market- https://www.delveinsight.com/report-store/radiation-dermatitis-market
ranibizumab biosimilars market- https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight
seasonal allergic rhinitis market- https://www.delveinsight.com/report-store/allergic-rhinitis-market
sly syndrome market- https://www.delveinsight.com/report-store/sly-syndrome-market
social anxiety disorder market- https://www.delveinsight.com/report-store/social-anxiety-disorder-market
soft tissue sarcoma with lung metastasis market- https://www.delveinsight.com/report-store/soft-tissue-sarcoma-with-lung-metastases-market
surgical bleeding market- https://www.delveinsight.com/report-store/surgical-bleeding-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Thyroid Eye Disease Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight here

News-ID: 4070726 • Views:

More Releases from DelveInsight Business Research LLP

ER+/ HER2 -ve Breast Cancer Clinical Trials Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
ER+/ HER2 -ve Breast Cancer Clinical Trials Appears Robust With 20+ Key Pharma C …
DelveInsight's, "ER positive, HER2 negative Breast Cancer Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in ER positive, HER2 negative Breast Cancer pipeline landscape. It covers the ER+/ HER2 -ve Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the ER+/ HER2 -ve Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further
Mastocytosis Clinical Trials Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Mastocytosis Clinical Trials Appears Robust With 10+ Key Pharma Companies Active …
DelveInsight's, "Mastocytosis Pipeline Insight 2025" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Mastocytosis pipeline landscape. It covers the Mastocytosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the
Hidradenitis Suppurativa Clinical Trials Appears Robust With 24+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Hidradenitis Suppurativa Clinical Trials Appears Robust With 24+ Key Pharma Comp …
DelveInsight's, "Hidradenitis Suppurativa Pipeline Insight 2025" report provides comprehensive insights about 24+ companies and 24+ pipeline drugs in Hidradenitis Suppurativa pipeline landscape. It covers the Hidradenitis Suppurativa Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead
Cutaneous Squamous Cell Carcinoma Clinical Trials Appears Robust With 45+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Cutaneous Squamous Cell Carcinoma Clinical Trials Appears Robust With 45+ Key Ph …
DelveInsight's, "Cutaneous Squamous Cell Carcinoma Pipeline Insight 2025" report provides comprehensive insights about 45+ companies and 45+ pipeline drugs in Cutaneous Squamous Cell Carcinoma pipeline landscape. It covers the Cutaneous Squamous Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cutaneous Squamous Cell Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in

All 5 Releases


More Releases for Thyroid

Thyroid Cancer Treatment Market Increasing Ageing Population and Thyroid Cancer …
The thyroid cancer treatment market is projected to grow with a moderate CAGR during the forecast period, i.e., 2021-2029 on account of the increasing healthcare expenditure and the rising prevalence of thyroid cancer. As per The American Society of Clinical Oncology, in 2020, 44,280 number of adults in the United States is estimated to suffer from thyroid cancer. Such increasing prevalence of thyroid cancer is further expected to drive the
Thyroid Gland Disorders Treatment Market Increasing incidence of Autoimmune Dise …
The global market for thyroid gland disorders features a consolidated vendor landscape with a handful of companies accounting for a major chunk of the global market, observes Transparency Market Research in a recent report. In 2016, the thyroid gland disorders treatment market was dominated by Merck KGaA and AbbVie, Inc., which collectively accounted for more than half of the market. It has been observed that despite the large pool of
Thyroid Gland Disorder Treatment Market: Increasing incidence of Autoimmune Dise …
The global market for thyroid gland disorders features a consolidated vendor landscape with a handful of companies accounting for a major chunk of the global market, observes Transparency Market Research in a recent report. In 2016, the thyroid gland disorders treatment market was dominated by Merck KGaA and AbbVie, Inc., which collectively accounted for more than half of the market. It has been observed that despite the large pool of
Increasing Incidence of Thyroid Gland Disorders Expected to Propel the Thyroid G …
Thyroid gland is made of thyroid cells that absorb iodine from food and convert it into triiodothyronine (T3) and thyroxine (T4). These hormones are released into the blood stream and play an important role in the regulation of metabolism. Thyroid gland disorders are defined as an abnormal release of thyroid hormones which may demand proper therapeutic agents to correct the disorder condition. This report studies the market in a view
Increasing Incidence of Thyroid Gland Disorders Expected to Propel the Thyroid G …
Thyroid gland is made of thyroid cells that absorb iodine from food and convert it into triiodothyronine (T3) and thyroxine (T4). These hormones are released into the blood stream and play an important role in the regulation of metabolism. Thyroid gland disorders are defined as an abnormal release of thyroid hormones which may demand proper therapeutic agents to correct the disorder condition. This report studies the market in a view
Increasing Incidence of Thyroid Gland Disorders Expected to Propel the Thyroid G …
The number of patients suffering from thyroid gland disorders across the globe is increasing at a rapid rate. This direct increase in demand is expected to be a primary driver for the development of thyroid gland disorder treatments. The number of patients with thyroid gland disorder is increasing due to a growing population of the elderly, who are prone to thyroid disorders and similar illnesses. Additionally, a person suffering from